Ranbaxy Laboratories Ltd has settled all matters relating to possible patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline's Imitrex tablets.
The terms of the settlement, provide that Ranbaxy may distribute a generic version of sumatriptan succinate tablets (in the 25 mg, 50 mg and 100 mg strengths) in the US with an expected launch date in December, 2008.
Additional terms of the settlement agreement were not disclosed.
The annual market sales for sumatriptan succinate (Imitrex®) were USD 985 million (IMS- MAT: Sept 2007).